Cargando…

Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018

BACKGROUND: People in prison report high rates of drug use and drug-related problems and people who use or inject drugs (PWUD) have higher rates of offending and an increased likelihood of spending part of their lives in prison. They represent a vulnerable population with high burden of diseases, so...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzilli, S, Royuela, L, Tavoschi, L, Vandam, L, Montanari, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593755/
http://dx.doi.org/10.1093/eurpub/ckac131.416
_version_ 1784815241047048192
author Mazzilli, S
Royuela, L
Tavoschi, L
Vandam, L
Montanari, L
author_facet Mazzilli, S
Royuela, L
Tavoschi, L
Vandam, L
Montanari, L
author_sort Mazzilli, S
collection PubMed
description BACKGROUND: People in prison report high rates of drug use and drug-related problems and people who use or inject drugs (PWUD) have higher rates of offending and an increased likelihood of spending part of their lives in prison. They represent a vulnerable population with high burden of diseases, socio-economic disadvantages and limited access to healthcare. In this study, we aimed to describe the lifetime prevalence (LTP) of heroin use, injected drug use and opioid agonist therapy (OAT) among people living in prison. METHODS: Individual data collection was carried out in seven European countries (Czech Republic, Latvia, Lithuania, Poland, Portugal, Slovenia, Spain) between 2014 and 2018 with a model European Questionnaire on Drug use among people in Prison. Risk factors analysis was carried out using multivariate logistic regression model. RESULTS: The analysis of EQDP data found that the LTP of heroin use was overall 22.4% (ranged from 7.3% in Poland to 27.5% in Spain). Female, recidivist offenders, individuals aged below 44 and with an history of mental health condition had a higher likelihood of being heroin user (p-value<0.05). The LTP of injected drug use was overall 20.6%(2176/10,587), while the prevalence of injected drug use in prison was 8.1%(745/9273) (with higher prevalence in countries that did not allow OAT initiation in prison: 17.5% in Latvia, 22.1% in Lithuania and 26.7% in Czech Republic). Among those who used heroin, 44.5%(772/1735) had access to OAT and among them 95.8(566/591) had access to OAT in prison. CONCLUSIONS: Despite the heterogeneity of the results, there is a clear evidence that people in prison have a high prevalence of heroin and injected drug use. Prisons are an important point of access to OAT, and where treatment is available there is a reduction in risk behaviour. It is also important to implement tailored preventive interventions among vulnerable social groups at the community level. KEY MESSAGES: • People in prison in Europe have a high prevalence of heroin and injected drug use. Prisons can represent a point of access to integrated prison-community healthcare and social services for PWUD. • In order to plan adequate healthcare interventions, there is an urgent need to assess and monitor the prevalence of drug use also in other European countries.
format Online
Article
Text
id pubmed-9593755
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95937552022-11-22 Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018 Mazzilli, S Royuela, L Tavoschi, L Vandam, L Montanari, L Eur J Public Health Poster Displays BACKGROUND: People in prison report high rates of drug use and drug-related problems and people who use or inject drugs (PWUD) have higher rates of offending and an increased likelihood of spending part of their lives in prison. They represent a vulnerable population with high burden of diseases, socio-economic disadvantages and limited access to healthcare. In this study, we aimed to describe the lifetime prevalence (LTP) of heroin use, injected drug use and opioid agonist therapy (OAT) among people living in prison. METHODS: Individual data collection was carried out in seven European countries (Czech Republic, Latvia, Lithuania, Poland, Portugal, Slovenia, Spain) between 2014 and 2018 with a model European Questionnaire on Drug use among people in Prison. Risk factors analysis was carried out using multivariate logistic regression model. RESULTS: The analysis of EQDP data found that the LTP of heroin use was overall 22.4% (ranged from 7.3% in Poland to 27.5% in Spain). Female, recidivist offenders, individuals aged below 44 and with an history of mental health condition had a higher likelihood of being heroin user (p-value<0.05). The LTP of injected drug use was overall 20.6%(2176/10,587), while the prevalence of injected drug use in prison was 8.1%(745/9273) (with higher prevalence in countries that did not allow OAT initiation in prison: 17.5% in Latvia, 22.1% in Lithuania and 26.7% in Czech Republic). Among those who used heroin, 44.5%(772/1735) had access to OAT and among them 95.8(566/591) had access to OAT in prison. CONCLUSIONS: Despite the heterogeneity of the results, there is a clear evidence that people in prison have a high prevalence of heroin and injected drug use. Prisons are an important point of access to OAT, and where treatment is available there is a reduction in risk behaviour. It is also important to implement tailored preventive interventions among vulnerable social groups at the community level. KEY MESSAGES: • People in prison in Europe have a high prevalence of heroin and injected drug use. Prisons can represent a point of access to integrated prison-community healthcare and social services for PWUD. • In order to plan adequate healthcare interventions, there is an urgent need to assess and monitor the prevalence of drug use also in other European countries. Oxford University Press 2022-10-25 /pmc/articles/PMC9593755/ http://dx.doi.org/10.1093/eurpub/ckac131.416 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Displays
Mazzilli, S
Royuela, L
Tavoschi, L
Vandam, L
Montanari, L
Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018
title Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018
title_full Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018
title_fullStr Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018
title_full_unstemmed Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018
title_short Prevalence of injected drug use and access to OAT in prison: survey in 7 EU countries, 2014-2018
title_sort prevalence of injected drug use and access to oat in prison: survey in 7 eu countries, 2014-2018
topic Poster Displays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593755/
http://dx.doi.org/10.1093/eurpub/ckac131.416
work_keys_str_mv AT mazzillis prevalenceofinjecteddruguseandaccesstooatinprisonsurveyin7eucountries20142018
AT royuelal prevalenceofinjecteddruguseandaccesstooatinprisonsurveyin7eucountries20142018
AT tavoschil prevalenceofinjecteddruguseandaccesstooatinprisonsurveyin7eucountries20142018
AT vandaml prevalenceofinjecteddruguseandaccesstooatinprisonsurveyin7eucountries20142018
AT montanaril prevalenceofinjecteddruguseandaccesstooatinprisonsurveyin7eucountries20142018